Live Chat
Today's Hours: 8:00am - 10:00pm
Lane Medical Library

Search

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Book
    Summary: This TIP reviews three Food and Drug Administration-approved medications for opioid use disorder treatment--methadone, naltrexone, and buprenorphine--and the other strategies and services needed to support people in recovery.

    Contents:
    Part 1: An introduction to medications for the treatment of opioid use disorder. The approach to OUD care
    Overview of medications for OUD
    Duration of treatment with OUD medication
    Treatment settings
    Challenges to expanding access to OUD medication
    Resources
    Notes
    Part 2: Addressing opioid use disorder in general medical settings. Scope of the Problem
    Screening
    Assessment
    Treatment planning or referral
    Resources
    Appendix
    Notes
    Part 3: Pharmacotherapy for opioid use disorder. Pharmacotherapy for opioid use disorder
    Overview of pharmacotherapy for opioid use disorder. Methadone
    Naltrexone
    Buprenorphine
    Medical management strategies for patients taking OUD medications in office-based settings
    Medical management of patients taking OUD medications in hospital settings
    PART 4: Partnering addiction treatment counselors with clients and healthcare professionals. Overview and context
    Quick guide to medications
    Counselor-prescriber communications
    Creation of a supportive counseling experience
    Other common counseling concerns
    Notes
    Part 5: Resources related to medications for opioid use disorder. General Resources
    Resources for counselors and peer providers
    Resources for clients and families
    Provider tools and sample forms
    Glossary of TIP terminology
    Notes
    Digital Access R2Library 2018
  • Article
    Fasiolo F, Fersht AR.
    Eur J Biochem. 1978 Apr;85(1):85-8.
    It is shown from a combination of rapid quenching and steady-state kinetics that the phenylalanyl-tRNA synthetase from yeast catalyses the formation of phenylalanyl-tRNA by the amino-acyladenylate pathway at pH 7.8 and 25 degrees C. The rate-determining step at saturating reagent concentrations is not the dissociation of the charged tRNA from the enzyme.
    Digital Access Access Options